Moreover, as PCa progresses under ARPI treatment, it can undergo trans-differentiation into neuroendocrine prostate cancer (NEPCa), a biological entity characterized by low or absent AR expression and aggressive behavior. Here, AR is linked to posterior cortical atrophy.